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The characteristics of sebaceous gland hyperplasia (SGH) consist of yellowish or skin-colored papules and
nodules. Chronic sun exposure and immunosuppressed conditions are the main environmental risk factors,
whereas chronological aging regulated by hormones and molecular changes are the intrinsic risk factors. We
have evaluated the contribution of BRAF, K-Ras, and N-Ras mutations to the pathogenesis of SGHs in four
patients belonging to three MYH-associated polyposis (MAP) pedigrees. MAP is an autosomal-recessive disease
characterized by multiple colorectal adenomas and cancer. Immunohistochemistry of mismatch repair and APC
proteins was performed. DNA isolated from blood lymphocytes and formalin-fixed or paraffin-embedded SGHs
was PCR amplified and sequenced. In the SGH patients, we detected T1796A heterozygous substitution (V600E)
in the BRAF gene. Compound biallelic germline MYH mutations (Y165C/G382D, R168H/379delC, and Y90X/
delGGA464) were detected in the MAP patients. In contrast to the majority of melanocytic lesions, activating
hotspot mutations in BRAF have not been involved so far in the pathogenesis of SGH. BRAF mutation is not a
specific marker of melanocytic cancerogenesis, and it can also be involved in SGHs. In both melanocytic and
non-melanocytic skin tumors, BRAF mutation is linked to early tumorigenesis events.
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INTRODUCTION
The characteristics of sebaceous gland hyperplasia (SGH)
consist of small, pale, yellowish, or skin-colored papules and
nodules (with a distinctive central umbilication), which
generally appear on the face of older individuals. Histologi-
cally, hyperplastic sebaceous glands are characterized by a
dilated follicular infundibulum plugged with keratin and by the
proliferation and enlargement of sebaceous lobules. A helpful
feature is the budding of lobules above a horizontal plane that
bisects the sebaceous ducts (Murphy and Elder, 1991).
SGH occurs at a rate of 1% in healthy populations, and in
16% of immune-suppressed organ transplant recipients (de
Berker et al., 1996). SGH is attributed to both extrinsic and
intrinsic factors: among extrinsic environmental conditions,
chronic sun exposure and immunosuppressed treatment
represent the main risk factors responsible for clinical and
histological changes of sebaceous glands, whereas the
genetically determined intrinsic factors are chronological
aging regulated by hormones (especially androgens) and
other molecular changes (Zoubolulis and Boschnakow,
2001). MYH-associated polyposis (MAP) is an autosomal-
recessive disease characterized by multiple colorectal ade-
nomas and cancer. MAP is caused by biallelic inactivating
mutations of the MYH gene, a component of the base
excision repair machinery, whose dysfunction leads to an
increase in the rate of G4T transversion following DNA
oxidative damage (Sampson et al., 2003).
The observation that some patients affected with MAP also
had multiple SGHs led to the hypothesis that these sebaceous
lesions could be associated with genetic changes and be
useful as clinical and biomolecular markers of specific
visceral inherited disorders (Ponti et al., 2005). Nevertheless,
it is known that SGH is not part of the Muir–Torre syndrome,
which typically manifests with tumors including sebaceous
adenoma and carcinoma or keratoacanthomas. The mole-
cular characterization of sebaceous hyperplasia showed a
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very low frequency of mismatch repair gene alterations and
microsatellite instability with respect to the high frequency
detected in sebaceous adenomas and carcinomas of Muir–-
Torre syndrome patients (Kruse et al., 2003).
In genetics studies, the regulation of sebaceous gland
functions has involved certain genes: overexpression of
Smad-7 and of parathormone-regulated protein in adult
transgenic mice has been correlated with sebaceous hyper-
plasia (Foley et al., 1998; He et al., 2001). Despite this
evidence, the known genetic changes in human SGH are few
and these lesions have not yet been characterized. It is of
interest to investigate the involvement of molecular pathways
implicated in other precancerous skin lesions. As BRAF
mutations were identified in the sporadic melanoma and also
in a large majority of precancerous skin lesions (especially in
cutaneous nevi) (Pollock et al., 2003), we have investigated
sebaceous hyperplasias for BRAF, N-Ras, and K-Ras muta-
tions, an additional component of the mitogen-activated
protein kinase-signaling pathway. BRAF is located on
chromosome 7q34 and encodes a serine/threonine kinase,
regulating proliferation and differentiation via the mitogen-
activated protein kinase system pathway (Satyamoorthy
et al., 2003).
RESULTS
Family 1
In 2004, a 53-year-old female patient underwent surgical
subcolectomy with ileo-rectum anastomosis for an attenuated
colonic polyposis (about 20 polyps). Her medical history was
characterized by the removal of multiple colonic polyps in
three colonoscopy procedures and by surgical treatment of
yellow skin lesions of the face (Figure 1), which resulted in
sebaceous hyperplasias at histology.
Despite the subcolectomy, the patient presented with
multiple anastomotic and rectal polyps in follow-up colono-
scopic surveillances. The same clinical history was shared by
the 58-year-old proband’s brother, who underwent a right
emicolectomy at 50 years for attenuated colonic polyposis
(about 25–30 adenomatous and hyperplastic colonic polyps)
located proximally and presented with multiple skin lesions
of the face, which resulted in sebaceous hyperplasia at
histology.
In their family, the mother died of endometrial cancer,
aged 81 years, and six paternal cousins were affected by late-
onset colon cancer (60–65 years) (Figure 2).
Family 2
A 32-year-old woman underwent right hemicolectomy in
1996 for cancer of the hepatic flexure and 22 tubulo-villous
adenomas. In 2001, the patient (aged 37 years) underwent
total thyroidectomy for papillary carcinoma. Because of a
diagnosis of about 30 adenomatous and hyperplastic polyps
during follow-up colonoscopies, the patient underwent
subsequent total colectomy with ileo-anal anastomosis and
J pouch. Multiple yellow papules, which resulted in seba-
ceous hyperplasia and adenoma at histology, had been
present on the face of the proband and on the forehead of her
11-year-old daughter.
In the family, the father died of non-Hodgkin’s lymphoma
at 68 years, and a paternal uncle died of transitional cell
carcinoma of the bladder at 57 years. One colonic adenoma
was removed in a brother and in a sister at ages 24 and 36
years, respectively.
Family 3
A 49-year-old man underwent surgical left hemicolectomy in
1994 for cancer and attenuated polyposis. For the previous
15 years, he had noted multiple asymptomatic yellow
papules of the forehead and face; histologically, these skin
lesions consisted of sebaceous hyperplasias.
The patient’s brother was diagnosed with colonic poly-
posis and died of colon cancer at the age of 50 years. There
was no history of bowel neoplasms in the patient’s mother or
father, both of whom had died at advanced ages.
We investigated four MAP patients with multiple seba-
ceous hyperplasias, examining one lesion for each individual;
pathologic diagnosis was performed in all cases. Immuno-
histochemistry was executed on paraffin-embedded tissues,
whereas the mutations analysis was conducted on fresh
tissue.
In the proband and brothers of family 1 (III-10, III-11,
Figure 1) and in the probands of family 2 and family 3,
sebaceous hyperplasias such as colorectal lesions were
assessed for microsatellite instability and mismatch repair
protein expression. Neither sebaceous hyperplasia nor
colonic polyps showed microsatellite instability, and mis-
match repair proteins (MLH1, MSH2, MSH6) were normally
expressed. In all sebaceous hyperplasias, Adenomatosis
Polyposis Coli (APC) protein was normally expressed.
Single-strand conformation polymorphism analysis
showed no mutations in K-Ras and N-Ras genes. The
sequence analysis of the APC gene revealed no mutations.
In all samples of sebaceous hyperplasia from four patients
belonging to three MAP syndromes, we detected T1796A
substitution on exon 15 of the BRAF gene (Figure 3). This
change causes acquisition of the activating mutation V600E.
It is known that this mutation activates a signaling cascade
Figure 1. Clinical appearance of SGHs in the face of the proband of family 1
affected by MAP.
1388 Journal of Investigative Dermatology (2007), Volume 127
G Ponti et al.
BRAF Mutations in Multiple Sebaceous Hyperplasias
involving protein in the mitogen-activated protein kinase
system; the result is cell proliferation (Davies et al., 2002).
Compound biallelic germline MYH mutations (Y165/
G382D) were detected in both siblings of family 1.
Compound biallelic MYH mutations (R168/379del C) were
identified in the proband of family 2, and compound biallelic
MYH mutations (Y90X/delGGA464) were found in the
proband of family 3 (Table 1). No BRAF mutations were
detected in any of the sporadic sebaceous hyperplasias
belonging to the five individuals not affected by MAP.
DISCUSSION
The most intriguing finding of this study is the detection of
BRAF mutations in multiple SGH in four affected individuals
from three MAP pedigrees.
Activating BRAF mutations were revealed in 80% of
primary melanomas, 68% of melanoma metastases (Davies
et al., 2002; Gorden et al., 2003), and 82% of cutaneous nevi
(Pollock et al., 2003). Human nevi frequently harbor
oncogenic mutations (predominantly V600E, where valine
is substituted with glutamic acid in the kinase domain of
protein) in the BRAF gene. Exon 15 is typically a target of
activating BRAF mutations either in sporadic cutaneous
melanoma or in nevi.
BRAF gene mutations have been identified in a wide range
of human tumors. Other than melanocytic tumors, benign
colorectal lesions and colorectal carcinomas (Yuen et al.,
2002), papillary thyroid carcinomas (Cohen et al., 2003), and
lung, head, and neck cancer (Davies et al., 2002; Naoki
et al., 2002) show exon 15 BRAF mutations. Activating
mutations in BRAF have recently been found in about 10% of
colorectal cancer cases, where it is mutually exclusive with
mutations in K-Ras, and showed distinctive phenotypic
properties independent of microsatellite status (Li et al.,
2006). Other evidence suggests that the BRAF gene mutation
is important for malignant transformation rather than pre-
malignant stages in the tumorigenesis of endometrioid-type
carcinomas (Feng et al., 2005). In addition, exon 15 somatic
point mutation in BRAF genes is a hallmark of unfavorable
clinicopathologic outcome for papillary carcinoma and
represents a therapeutic target in aggressive thyroid cancer
(Salvatore et al., 2006).
However, among the cutaneous neoplasms, the V600E
mutation was considered a specific marker for melanocytic
tumors (Helmke et al., 2004; Saldanha et al., 2004). It has
been shown that this alteration (National Center for
Biotechnology Information (NCBI) gene bank renamed the
V599E mutation based on newly available sequence data;
accession number NM_004333.2; hereafter referred to as
BRAFE600) causes the growth of carcinoma cell lines
independent of Ras activation (Davies et al., 2002); so far
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Figure 3. T1796A heterozygous substitution (V600E) in the SGHs of MAP
patients.
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no BRAF gene mutations have been predetermined in
multiple sebaceous hyperplasias.
Recently, evidence on melanocyte proliferation showed
that BRAFE600 contributes to early tumorigenic events and
leads to a growth-inhibitory response, associated with stable
proliferative arrest, an increase in p16INK4a, and induction of
SA-B-Gal activity (the known classical hallmarks of senes-
cence) (Michaloglov et al., 2005). Similarly, in benign SGHs,
the BRAF V600E mutation is involved in the early prolifera-
tion events of abnormal sebaceous glands.
Although SGH is not part of the Muir–Torre syndrome
clinical definition, some evidence showed an association
between these skin lesions and colonic polyposis (Finan and
Connolly, 1984), as in our recent report in which these
lesions were associated with MYH mutation patients (Ponti
et al., 2005). These cases reveal that SGH can be included
among extracolonic manifestations of MAP syndrome and
clarify their pathogenesis linked to BRAF gene mutations.
The MAP syndrome resulting from biallelic MYH muta-
tions is characterized by an autosomal-recessive attenuated
colonic polyposis. Few data are available on the extracolonic
features in MAP; however, congenital hypertrophy of the
retinal pigment epithelium, melanoma, dental abnormalities,
dermoid cysts, and osteoma have been described (Enholm
et al., 2003; Sampson et al., 2003). BRAF mutations have not
been reported previously in colorectal and extracolonic
tumors of MAP patients.
In malignant melanomas, the evaluation of mutational
profiles associated with BRAF mutation showed high-
frequency p53 and PTEN mutations such as loss of functional
p16/ARF (Daniotti et al., 2004). In endometrial cancer, BRAF
mutation was more frequently found associated with an
abnormal mismatch repair function (Feng et al., 2005). A
previous study detected no BRAF mutations at the codon 599
hotspot or elsewhere in exon 14 in MAP colorectal tumors
(Lipton et al., 2003). Therefore, although the role of MYH in
sebaceous carcinogenesis is unknown, our evidence of the
coexistence of germline MYH mutations and somatic BRAF
mutations permits us to hypothesize about functional over-
lapping among these two molecular pathways.
Systematic searches of somatic BRAF mutations in cancer
cells of individuals belonging to hereditary cancer syndrome
pedigrees will provide more information on the role of
concomitant molecular pathway alterations underlying heri-
table human cancerogenesis.
BRAF mutation is not a specific marker of melanocytic
tumors and can be responsible even for sebaceous cutaneous
hyperplasia. In contrast to colon, endometrial, and thyroid
cancers in which BRAF hotspot mutation is a marker of
malignant transformation, in melanocytic and non-melano-
cytic cutaneous neoplasms BRAF mutations can be detected
in the early phases of skin tumorigenesis.
These results have important clinical implications because
the detection of BRAF mutations in prevalent readily
accessible multiple sebaceous hyperplasia could form the
basis of endoscopic and biomolecular screening for MAP.
MATERIALS AND METHODS
Microsatellite testing, immunohistochemistry, single-strand
conformation polymorphism, and gene mutation analysis
For microsatellite analysis, DNA was extracted from neoplastic and
paired normal mucosa specimens of cutaneous lesions and visceral
malignancies, as described previously in more detail (Pedroni et al.,
1999). Five markers – three mononucleotides (BAT25, BAT26, and
BAT40) and two dinucleotides (D17S787, D18S58) – were used;
tumors showing instability at two or more loci were scored as
‘‘unstable’’ (Boland et al., 1998).
The immunohistochemical evaluation of MSH6, MLH1, MSH2,
and APC protein expression was carried out in paraffin-embedded
tumor samples. Immunoperoxidase staining, using diaminobenzi-
dine as a chromogen, was carried out with the NEX-ES, Automatic
Staining System (Ventana, AZ). The mouse mAbs used were anti-
MSH6 (clone 44, Transduction Labs, Biosciences, Milano, Italy) at
1:2,000 dilution, anti-MLH1 (G168-15, Pharmingen, San Diego, CA)
at 1:40 dilution, and anti-MSH2 (G129-1129, Pharmingen) at 1:40
dilution. In normal tissues, the nucleus shows clear staining with all
antibodies. Neoplasms in which one of the proteins was inactivated
did not show nuclear staining. Mouse mAb anti-APC (Abcam,
Cambridge, UK) at 1:500 dilution was used. APC immunoreactivity
was present in the cytoplasm of the goblet cells of normal colonic
mucosa and in keratinocytes. Altered expression of APC was
considered when the absence of cytoplasmic staining was seen in
neoplastic cells.
Single-strand conformation polymorphism analysis of the K-Ras
gene was performed as described previously (Losi et al., 2004).
B-RAF exon 15 and N-RAS exons 1 and 2 were subjected to PCR
amplifications using primers reported previously (Demunter et al.,
2001). Briefly, for all exons thermal cycling was carried out in a final
volume of 50ml containing 100mM of each deoxynucleoside
triphosphate, 10 pmol of primers, 3 ml of DNA extract, and 5 U of
Table 1. Patients with both biallelic germline MYH mutations and somatic BRAF mutations
Patient/family
Age
(years)
Skin
lesions
BRAF somatic
mutation
Visceral
lesions
MYH germline
mutations
Patient 1/family 1 56 Sebaceous hyperplasias V600E Attenuated colonic polyposis Y165C/G382D
Patient 2/family 1 59 Sebaceous hyperplasias V600E Attenuated colonic polyposis Y165C/G382D
Patient 1/family 2 37 Sebaceous hyperplasias and adenoma V600E Colonic carcinoma and attenuated polyposis 379delC/R168H
Patient 2/family 2 9 Sebaceous hyperplasias — — 379delC/-
Patient 1/family 3 49 Sebaceous hyperplasias V600E Attenuated colonic polyposis Y90X/delGGA664
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Taq polymerase (Thermoprime Plus DNA Polymerase, Abgene,
Milion SA, Geneva, CH). The amplification protocol used consisted
of an initial denaturation of 4 minutes followed by 40 cycles with
denaturation at 941C for 45 seconds, annealing at 551C for
45 seconds, and extension at 721C for 1 minute and 30 seconds.
PCR products were purified by a MinElute Gel Extraction Kit
(Qiagen, Hilden, Germany) and directly sequenced on both strands
using a Prism Model 3700 Capillary Array sequencer.
Mutational analysis of APC and the MYH gene was performed on
genomic DNA isolated from peripheral blood lymphocytes using a
QIAMP DNA mini Kit (Qiagen). All exons of APC and MYH were
directly sequenced using a Dye Terminator Cycle Sequencing Kit
and a CEQ 8000 DNA sequencer (Beckman Coulter, Follerton, CA)
(Ponti et al., 2005).
The study was conducted according to the Declaration of
Helsinki Principles, and institutional approval and written informed
patient consent were obtained.
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